Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.
Ilari Virtanen, Pietari Mäkelä, Teija Sainio et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, single-arm pilot study evaluated the effects of 3-month neoadjuvant androgen deprivation therapy (nADT) with degarelix on prostate and tumor morphology in 15 treatment-naïve patients with intermediate-risk prostate cancer. The study found that nADT led to a significant 26% reduction in prostate volume and an 87% decrease in PSA levels, suggesting improved feasibility for MRI-guided transurethral ultrasound ablation.
Key findings
- PSA levels decreased by 87% (-7.6 ng/mL; p < 0.001) after nADT.
- Prostate volume reduced by 26% (-15 mL; p < 0.001) following treatment.
- Index lesion volume decreased by 69% (-0.8 mL; p < 0.001).
- Capsule bulging resolved in four of seven patients.
Why it matters
The findings indicate that neoadjuvant androgen deprivation therapy may enhance the feasibility of thermal ablation techniques for prostate cancer by significantly reducing prostate and tumor size, potentially improving treatment outcomes.